Headlines about Iovance Biotherapeutics (NASDAQ:IOVA) have trended somewhat positive on Friday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Iovance Biotherapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.4371500821728 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Iovance Biotherapeutics (NASDAQ:IOVA) opened at $8.90 on Friday. The company has a market cap of $646.43, a PE ratio of -6.79 and a beta of 4.89. Iovance Biotherapeutics has a 1-year low of $4.45 and a 1-year high of $9.54.
Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). research analysts expect that Iovance Biotherapeutics will post -1.37 earnings per share for the current year.
A number of brokerages recently weighed in on IOVA. Zacks Investment Research lowered shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 4th. BidaskClub lowered shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 22nd. B. Riley reaffirmed a “buy” rating and issued a $18.00 price target on shares of Iovance Biotherapeutics in a research note on Wednesday, December 13th. HC Wainwright set a $16.00 price target on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Thursday, December 14th. Finally, Oppenheimer set a $13.00 price target on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Thursday, December 14th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Iovance Biotherapeutics has a consensus rating of “Buy” and a consensus price target of $14.61.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/12/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-iovance-biotherapeutics-iova-stock-price.html.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.